Organization | Alberta Heritage Foundation for Medical Research

Alberta Heritage Foundation for Medical Research Report issue

Foundation Phase 2 Phase 3

Founded: Canada (1980)

Organization Overview

First Clinical Trial

1996

NCT00175227

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2011

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (2)

alendronic acid (fosamax) (1 trial)

risedronate (actonel) (1 trial)

Drugs in Phase 2 Trials (10)

cyanocobalamin (berocca) (1 trial)

enalapril (vasotec) (1 trial)

fish oil (Omegavan) (1 trial)

hydralazine (apresoline) (1 trial)

labetalol (trandate) (1 trial)

magnesium oxide (1 trial)

pyridoxine (1 trial)

vitamin c (1 trial)

vitamin e (1 trial)

xanthaurine (1 trial)

Drugs in Other Trials (3)

furosemide (lasix) (1 trial)

mannitol (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Asthma (Phase 2)

Cerebral Hemorrhage (Phase 2)

Hemorrhage (Phase 2)

Hip Fractures (Phase 3)

Osteoporosis (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial APIs: 15